Ionis Pharmaceuticals (Ionis Pharmaceuticals) EBIT per Share : $-1.81 (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals EBIT per Share?

Ionis Pharmaceuticals's EBIT per Share for the three months ended in Dec. 2023 was $0.13. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.81.

During the past 3 years, the average EBIT per Share Growth Rate was -32.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Ionis Pharmaceuticals's EBIT per Share or its related term are showing as below:

IONS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -72.9 Med: 2.6 Max: 44.3
Current: -32

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Ionis Pharmaceuticals was 44.30% per year. The lowest was -72.90% per year. And the median was 2.60% per year.

IONS's 3-Year EBIT Growth Rate is ranked worse than
82.43% of 1303 companies
in the Biotechnology industry
Industry Median: 3.4 vs IONS: -32.00

Ionis Pharmaceuticals's EBIT for the three months ended in Dec. 2023 was $18.1 Mil.

Ionis Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Ionis Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals EBIT per Share Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

2.29

-0.92

-0.18

-1.80

Ionis Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.31	-0.68	-0.41	-0.84	0.13

Ionis Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Ionis Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-258.368	/	143.190
=	-1.80

Ionis Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	18.082	/	143.604
=	0.13

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.81

Ionis Pharmaceuticals (NAS:IONS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Ionis Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

IONS:Mexico ISI:Germany ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Executives

Brian Birchler	officer: EVP, Corp and Development Ops	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Patrick R. O'neil	officer: SVP, Legal and General Counsel	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier	officer: Chief Corp Dev and Cml Officer	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider	officer: EVP, Chf Clinical Develop Offc	C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Joseph Baroldi	officer: Chief Business Officer	C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eric Swayze	officer: SVP, Research	2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia	director, officer: Senior Vice President	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary	officer: Senior Vice President	2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen	officer: SVP, Finance and CFO	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett	officer: Vice President	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
B Lynne Parshall	director, officer: Executive Vice President, CFO	2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Iii Klein	director	C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Spencer R Berthelsen	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Frederick T Muto	director	2855 GAZELLE COURT, CARLSBAD CA 92010